This is the authors' abstract. We don't add key points for this paper.
Background The optimal duration of antibiotic therapy in septic arthritis varies according to joint type, surgical strategy, host immune status and microbiological profile. While adequately drained native joints allow for short treatment courses, prosthetic joint infections, complicated by biofilm formation, often require prolonged regimens. However, no simple bedside tool currently exists to individualise treatment duration. Objective To describe the AJISS score (Age–Joint–Immunity–Surgery–Sensitivity), derived from a systematic review and meta analysis of randomised controlled trials, and to propose duration thresholds based on its predictive performance. Methods Randomised controlled trials comparing short versus prolonged antibiotic courses were synthesised. The AJISS score combines five clinical dimensions: age (0–2), joint type (0–1), immune status (0–2), surgical strategy/biofilm control (0–3), and antibiotic susceptibility (0–2). A logistic model relating the total AJISS score to the probability of therapeutic success was used to define duration categories. Results The logistic relation followed the equation logit(Psuccess)=3.0−0.33×AJISS, with acceptable discrimination (AUC≈0.78) and an almost linear inverse correlation between score and success probability. Three operational thresholds emerged: AJISS 0–2 was associated with a high probability of cure and a recommended duration of 3–4 weeks; AJISS 3–5 suggested 6–8 weeks; AJISS 6–9 indicated ≥12 weeks. These recommendations align with convergent findings from randomised evidence: short courses are effective for adequately drained native joints, whereas prosthetic joint infections benefit from prolonged therapy, particularly in the presence of mature biofilm or conservative surgical strategies. Conclusion The AJISS score provides a simple, reproducible framework to tailor antibiotic duration in septic arthritis according to individual risk. It offers clear clinical readability while remaining consistent with available randomised evidence. A multicentre external validation is underway to confirm the proposed thresholds and integrate additional prognostic biomarkers.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Bombah et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: